Medicenna Therapeutics Corp. (TSE:MDNA – Get Free Report)’s share price shot up 1.6% on Thursday . The stock traded as high as C$1.98 and last traded at C$1.87. 29,147 shares traded hands during trading, a decline of 72% from the average session volume of 102,571 shares. The stock had previously closed at C$1.84.
Medicenna Therapeutics Stock Performance
The company has a debt-to-equity ratio of 0.06, a current ratio of 2.51 and a quick ratio of 4.65. The firm has a market cap of C$142.92 million, a P/E ratio of -4.92 and a beta of 1.21. The stock’s 50 day moving average is C$1.94 and its two-hundred day moving average is C$2.04.
Medicenna Therapeutics Company Profile
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors.
Recommended Stories
- Five stocks we like better than Medicenna Therapeutics
- Are Penny Stocks a Good Fit for Your Portfolio?
- Top 3 Investment Themes to Watch for in 2025
- Investing in Construction Stocks
- Mega Buybacks in 2025: Why These 3 Leading Stocks Are Buys
- What is a Dividend King?
- AMD vs. NVIDIA: The Better Semiconductor Bet for 2025
Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
